Anti-CD19 CAR NK cells is named as a drug or biological intervention in 2 clinical trials in our China trial register, 2 of which are recruiting. Lead sponsors include Changzhou No.2 People's Hospital (1) and The First Affiliated Hospital with Nanjing Medical University (1). Registered phase: Phase EARLY_PHASE1. Conditions studied include Thrombocytopenia Alloimmune; Antisynthetase Syndrome; Rheumatoid Arthritis.
| NCT ID | Study | Phase | Status |
|---|---|---|---|
| NCT06337474 | An Clinical Study of CD19 CAR NK Cells for the Treatment of Refractory Primary Immune Thrombocytopenia (ClinicalTrials.gov ↗) Thrombocytopenia Alloimmune |
Phase EARLY_PHASE1 | Recruiting |
| NCT06613490 | An Exploratory Clinical Study of CD19 CAR NK Cells for the Treatment of Refractory Antisynthetase Antibody Syndrome and Rheumatoid Arthritis (ClinicalTrials.gov ↗) Antisynthetase Syndrome, Rheumatoid Arthritis |
Phase EARLY_PHASE1 | Recruiting |
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
| Condition (as registered) | Trials |
|---|---|
| Thrombocytopenia Alloimmune | 1 |
| Antisynthetase Syndrome | 1 |
| Rheumatoid Arthritis | 1 |
| Lead sponsor | Trials |
|---|---|
| Changzhou No.2 People's Hospital | 1 |
| The First Affiliated Hospital with Nanjing Medical University | 1 |
| Register | Anti-CD19 CAR NK cells trials |
|---|---|
| Clinical trials in China | 2 |
A trial with sites in more than one country appears in each of those registers.
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how Anti-CD19 CAR NK cells works or whether it is effective. Each trial links to its own record so you can check it yourself.
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists Anti-CD19 CAR NK cells (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 24 Sep 2026.